Autoantibodies (Abs) to steroid 21-hydroxylase (21-OH) are a major component of adrenal cortex Abs and are characteristic of autoimmune Addison's disease. We have developed a new method for measuring Abs to 21-OH based on 125 I-labeled recombinant human 21-OH produced in yeast. With this assay, 21-OH Abs were detected in 43 of 60 (72%) sera from patients with isolated Addison's disease, 11 of 12 (92%) autoimmune polyglandular syndrome type I sera, 27 of 27 (100%) autoimmune polyglandular syndrome type II sera, and 24 of 30 (80%) sera from patients who were positive for adrenal cortex antibodies by immunofluorescence but had no overt Addison's disease. 21-OH Abs were found by 125 I assay in 4 of 150 (2.7%) sera from patients with insulin-dependent diabetes mellitus, 1 of 77 (1.3%) Graves' sera, 1 of 67 (1.5%) Hashimoto's sera, and 6 of 243 (2.5%) sera from healthy blood donors. 21-OH Abs were not detected in 9 sera from patients with Addison's disease due to tuberculosis, 32 sera from patients with noninsulin-dependent diabetes mellitus, 35 sera from patients with myasthenia gravis, or 17 sera from patients with premature ovarian failure. There was good agreement between the 125 Ilabeled 21-OH assay and an assay based on 35 S-labeled 21-OH produced in an in vitro transcription/translation system (r ϭ 0.86; n ϭ 129; P Ͻ 0.001). In the case of sera from patients with Addison's disease, insulin-dependent diabetes mellitus, Graves' disease, and Hashimoto's disease and from healthy blood donors that were low positive in the 125 I assay, neutralization studies with unlabeled 21-OH confirmed the presence of specific 21-OH Abs.
I-labeled recombinant human 21-OH produced in yeast. With this assay, 21-OH Abs were detected in 43 of 60 (72%) sera from patients with isolated Addison's disease, 11 of 12 (92%) autoimmune polyglandular syndrome type I sera, 27 of 27 (100%) autoimmune polyglandular syndrome type II sera, and 24 of 30 (80%) sera from patients who were positive for adrenal cortex antibodies by immunofluorescence but had no overt Addison's disease. 21-OH Abs were found by 125 I assay in 4 of 150 (2.7%) sera from patients with insulin-dependent diabetes mellitus, 1 of 77 (1.3%) Graves' sera, 1 of 67 (1.5%) Hashimoto's sera, and 6 of 243 (2.5%) sera from healthy blood donors. 21-OH Abs were not detected in 9 sera from patients with Addison's disease due to tuberculosis, 32 sera from patients with noninsulin-dependent diabetes mellitus, 35 sera from patients with myasthenia gravis, or 17 sera from patients with premature ovarian failure. There was good agreement between the 125 Ilabeled 21-OH assay and an assay based on 35 S-labeled 21-OH produced in an in vitro transcription/translation system (r ϭ 0.86; n ϭ 129; P Ͻ 0.001). In the case of sera from patients with Addison's disease, insulin-dependent diabetes mellitus, Graves' disease, and Hashimoto's disease and from healthy blood donors that were low positive in the 125 I assay, neutralization studies with unlabeled 21-OH confirmed the presence of specific 21-OH Abs.
Overall, the 21-OH Ab assay based on 125 I-labeled 21-OH showed good sensitivity, precision, and disease group specificity. This, combined with a simple assay protocol and the convenience of 125 I handling and counting, make it attractive for routine use. S TEROID 21-hydroxylase (21-OH) is a major adrenal autoantigen, and 21-OH autoantibodies (Abs) are important markers of autoimmune adrenal disease (1) (2) (3) . This is the case whether the disease presents as isolated Addison's disease or as a part of the autoimmune polyglandular syndromes (APS) type I or type II (4) .
A convenient assay for 21-OH Abs would be of considerable value in the diagnosis and management of autoimmune adrenal disease, and we now describe such a method and its application to the analysis of different patient groups. In the assay, 125 I-labeled recombinant human 21-OH is allowed to react with 21-OH Abs in test sera, and the immune complexes formed precipitate with solid phase protein A. 18 -68 yr) . In addition, sera from 243 healthy blood donors were obtained. Sera from patients with Hashimoto's thyroiditis were highly positive for thyroglobulin and/or thyroid peroxidase Abs (7), and sera from Graves' patients were positive for TSH receptor Abs (8) . All IDDM sera were positive for Abs to the 65-kDa isoform of glutamic acid decarboxylase (GAD 65 ) (9) , and all myasthenia gravis sera were positive for acetylcholine receptor Abs (10) . The Abs in the above patient groups were measured with reagents available from RSR (Cardiff, UK). Disease diagnosis was based on clinical, immunological, and biochemical grounds.
Materials and Methods

Patient sera
plasmid (pYES2/21-OH1) as described previously (5, 11) . Saccharomyces cerevisiae strain c13ABYS86 (12) was transformed with the plasmid containing the 21-OH cDNA using the lithium chloride method (13) . Yeast transformed with pYES2 plasmid not carrying 21-OH cDNA was used as the control. Transformants were grown, harvested, broken, and extracted as described previously (5, 14, 15) . The extracts of 21-OH were purified by hydrophobic chromatography on octyl-Sepharose (Pharmacia, St. Albans, UK) followed by hydroxyapatite (Sigma Chemical Co., Dorset, UK) chromatography as described previously (5, 14, 15) . The purity of 21-OH in the column fractions was assessed by electrophoresis on 9% polyacrylamide gels (SDS-PAGE) (16) , and total protein content was measured by Bradford assay (17) using reagents from Bio-Rad (Hemel Hempstead, UK).
21-OH Ab assay based on 125 I-labeled 21-OH expressed in yeast
Recombinant, purified human 21-OH was labeled with 125 I to a specific activity of 500 kilobecquerels/g protein using the chloramine-T method (18) . After purification by gel filtration (Sephacryl S-300, Pharmacia), 50-L aliquots of labeled material [30,000 -40, After 18-h incubation, 50 L solid phase protein A (RSR) were added, and incubation was continued for 1 h at 4 C. Tris buffer (1 mL) was then added, and after centrifugation (1500 ϫ g for 30 min at 4 C), the supernatants were aspirated, and the pellets were counted for 125 I.
Production of 35 S-labeled human recombinant 21-OH and
35
S immunoprecipitation assay 35 S-Labeled human 21-OH was prepared using plasmid pYES2/21-OH1 in an in vitro transcription/translation system (Promega, Southampton, UK) as described previously (4, 6, 19) and stored in aliquots at Ϫ70 C (for up to 1 month). The 35 S-labeled material was then used to measure 21-OH Abs in an immunoprecipitation assay as described in detail previously (6) . Negative control and positive reference sera were included in each assay. The negative control consisted of sera pooled from 20 individual healthy blood donors. The positive reference was serum from a patient with Addison's disease with high levels of 21-OH Abs. Results were expressed as a 21-OH Ab index calculated as 100 ϫ [cpm (unknown) Ϫ (negative control)]/[cpm (positive reference) Ϫ cpm (negative control)]. An index value of 2.6 or greater (based on a mean Ϯ 3 sd of 26 healthy blood donors) was considered to indicate the presence of 21-OH Abs. 
Measurement of recombinant human 21-OH
SDS-PAGE and Western blotting
Protein preparations were run (together with Sigma 6-H mol wt markers) on 9% SDS-PAGE under reducing conditions and either stained with Coomassie brilliant blue or blotted onto nitrocellulose membranes. Western blot analysis was carried out according to the method of Birk and Koepsell (20) using either mouse monoclonal antibody (RSR) or rabbit antibody to a glutathione-S-transferase-21-OH fusion protein (RSR) (21) . The reactions were developed using antimouse or antirabbit horseradish peroxidase conjugate followed by ECL reagents (Amersham International, Little Chalfont, UK).
Immunofluorescence studies
ACA were detected by a classical indirect immunofluorescence technique, using thin cryostatic sections of normal bovine adrenal gland as the source of antigen and fluorescein isothiocyanate-conjugated goat antihuman IgG, as previously described (22) . Sera were tested undiluted, and if positive, ACA titers determined by retesting sera in serial 2-fold dilutions until reaching the end point.
Results
Cultures of yeast transformed with pYES2/21-OH1 contained 4.7 Ϯ 1.3 mg 21-OH/L (mean Ϯ sd; n ϭ 5). Analysis by SDS-PAGE and Western blotting of 21-OH at different stages of purification is shown in Fig. 1, a and b . On SDS gels stained with Coomassie blue, a 55-kDa band representing 21-OH was clearly evident after one run on hydrophobic chromatography (Fig. 1a, lane 3) . Finally, purified material ran essentially as a single 55-kDa band (Fig. 1a, lane 4) . When the same samples were analyzed by Western blotting using a monoclonal antibody to 21-OH, a 55-kDa band representing 21-OH was clearly identified in the various preparations from yeast transformed with pYES2/21-OH1 plasmid (Fig.  1b, lanes 2-4) . There was no reactivity of the 21-OH monoclonal antibody with preparations of yeast transformed with control plasmid (i.e. not containing the 21-OH cDNA; lane 1 in Fig. 1, a and A 21-OH Ab standard curve was prepared using dilutions of a high 21-OH Ab-positive serum. In the presence of 1 U/mL (arbitrary units) of the standard, about 4% of [
125 I]21-OH was bound, increasing to about 65% in the presence of 100 U/mL. The mean Ϯ sd 21-OH Ab level in sera from 243 healthy blood donors was 0.081 Ϯ 0.364 U/mL, suggesting a lower detection limit (based on this mean Ϯ 3 sd) of approximately 1 U/mL.
The [ 125 I]21-OH Ab assay interassay coefficient of variation was 1.5% (n ϭ 6) for serum with higher levels of 21-OH Abs (mean, 13.9 U/mL), 2.2% (n ϭ 6) for serum with medium levels of 21-OH antibodies (mean, 9.8 U/mL), and 2.6% (n ϭ 6) for serum with lower levels of 21-OH Abs (mean, 3.1 U/mL). The intraassay coefficient of variation was 1.3% (n ϭ 6) for serum with higher levels of 21-OH Abs (mean, 13.9 U/mL), 2.1% (n ϭ 6) for serum with medium levels of 21-OH Abs (mean, 9.9 U/mL), and 2.2% (n ϭ 6) for serum with lower levels of 21-OH Abs (mean, 3.2 U/mL).
The results of 21-OH Ab measurements using the [ 125 I]21-OH Ab assay in sera from healthy blood donors, patients with autoimmune adrenal disease, and patients with other autoimmune and nonautoimmune diseases are shown in Fig.  3 and Table 1 . In the case of sera from healthy blood donors, 6 of 243 showed 21-OH Ab levels greater than 1 U/mL (1.1, 1.1, 1.2, 1.5, 3.4, and 3.7 U/mL). The 21-OH Ab activity in all six of the sera could be readily neutralized by the addition of unlabeled 21-OH (for examples, see Table 2 ).
Of 60 Addison's sera, 43 (72%) were positive for 21-OH Abs in the assay based on [
125 I]21-OH. Eleven of 12 (92%) APS type I sera, all 27 (100%) APS type II sera, and 24 of 30 (80%) sera from ACA-positive patients without overt Addison's disease were positive for 21-OH Abs. None of the 9 sera from patients with Addison's disease due to tuberculosis was positive. In the autoimmune control group, 21-OH Abs, albeit at low levels, were detected in 4 of 150 (2.7%) IDDM sera, 1 of 77 (1.3%) Graves' sera, and 1 of 67 (1.5%) sera from patients with Hashimoto's thyroiditis. No 21-OH Abs were found in the 35 patients with myasthenia gravis we studied or in the NIDDM (n ϭ 32) or POF (n ϭ 17) groups (Fig. 3) .
There Fig. 4 ). However, there were a few discrepancies (Fig. 4 and Table 1 ). One Addison's serum that was low positive in the 35 S assay (21-OH Ab index of 3.0) was negative in the 125 I assay. In contrast, 6 sera that were negative in the 35 S assay were low positive in the 125 I assay (from 1.1-3.1 U/mL).
The relationship between 21-OH Ab results with the 125 I assay and ACA by immunofluorescence is shown in Table 1 . Although there was good overall agreement between these assays, 9 sera (4 Addison, 2 APS type I, and 3 APS type II) that were negative for ACA by immunofluorescence were positive for 21-OH Abs by 125 I assay (range, 1.1-8.7 U/mL). Also, 7 sera that were ACA positive by immunofluorescence (6 ACA-positive patients without overt Addison's disease and 1 ACA-positive Addison's patient) were negative for 21-OH Abs by 125 I assay. In the group of patients with adrenal failure (isolated Addison's disease, APS type I, and APS type II; Table 1), 16 sera had levels of 21-OH Ab between 1-10 U/mL (i.e. lower levels) as measured by 125 I assay. However, only 8 (50%) of these sera had detectable ACA by immunofluorescence. To confirm the specificity of 21-OH Ab measurements, neutralization studies were carried out on some sera using unlabeled 21-OH, as shown in Table 2 . Addition of unlabeled 21-OH neutralized 21-OH Abs in all sera shown, including low positive sera from healthy blood donors, IDDM, and Graves' patients. A similar effect was observed with 21-OH Abs in Addison's sera ( Table 2) . Addition of unlabeled control proteins produced in yeast; recombinant GAD 65 and YP50 (a 50-kDa protein isolated from yeast transformed with control plasmid pYES2) had no effect. Further studies were carried out on the healthy blood donor serum that had a 21-OH Ab level of 3.7 U/mL. In particular, this serum was serially diluted in 21-OH Ab-negative human serum and reassayed. This showed that the serum 21-OH Ab had a similar dilution profile to 21-OH Ab in Addison's sera (data not shown). Furthermore, increasing concentrations (0.15-60 g/mL serum) of unlabeled 21-OH had a similar effect on 125 I-labeled 21-OH binding to 21-OH Ab in this healthy blood donor serum and 21-OH Ab in Addison's sera (data not shown). In these experiments, 3.6 L Tris buffer or unlabeled preparations of recombinant 21-OH (370 g/mL), unlabeled recombinant GAD 65 produced in yeast (370 g/mL) or unlabeled preparations of yeast protein YP50 (370 g/mL) were added to 50 L undiluted patient sera and preincubated for 24 h at 4 C; thereafter, the 125 I assays were carried out as described in the text.
NT, Not tested. a The dilution effect of adding buffer to the serum sample resulted in slightly lower values (units per mL) for 21-OH Ab than quoted in the text. 
Discussion
Our results show that recombinant human 21-OH produced in yeast can be purified, labeled with 125 I, and used in a sensitive, specific, and convenient immunoprecipitation assay for 21-OH Abs.
The amount of extractable recombinant 21-OH in yeast cells was about 150 g/g cells, and this can be compared to about 200 g native 21-OH/g human adrenal tissue (data not shown). However, human adrenal tissue is not readily available in large amounts, and this limitation explains in part why preparations of native human 21-OH have not been used for 125 I labeling. In contrast, yeast can be grown easily and safely on a relatively large scale. In addition to being a useful expression system for producing 21-OH, yeast can be used to produce other important human autoantigens, including glutamic acid decarboxylase (9) .
Using our assay based on 125 I-labeled 21-OH, we could detect 21-OH Abs in 43 of 60 (72%) Addison's sera. This can be compared with prevalences of 64 -86% for 21-OH Abs in Addison's patients reported by different laboratories using 35 S-labeled 21-OH based assays or immunoblotting analysis (4 -6, 23-25) . A high prevalence of 21-OH Abs was also observed in APS type I and APS type II sera (11 of 12 and 27 of 27, respectively) using 125 I-labeled 21-OH. The one 21-OH Ab-negative APS type I patient had hypoparathyroidism, candidiasis, Addison's disease, vitiligo, alopecia, and keratopathy. His brother also had APS type I with the same clinical symptoms, but was in the 21-OH Ab-positive group. Our previous data (4, 6) and reports by Song et al. (24) and Uibo et al. (26) have shown similar prevalences of 21-OH Ab in APS type I and type II. These results strongly support the concept that 21-OH is a major autoantigen in autoimmune adrenal disease.
There was good agreement between 21-OH Ab results obtained by 125 I and 35 S assays (r ϭ 0.86; n ϭ 129). Only one serum (ACA negative) that was low positive in the 35 S assay was negative by 125 I assay, whereas six sera that were negative by 35 S assay were positive in the 125 I assay. These six sera were from patients with a clinical diagnosis of Addison's disease (two isolated Addison, three APS type I, and one APS type II), although all but one were negative for ACA. In contrast to the 35 S assay, undiluted serum was used with 125 I-labeled 21-OH, and this should allow detection of Abs present at lower concentrations. In addition, the precision of the 125 I assay was good, with inter-and intraassay coefficients of variation of about 2%. Overall, therefore, the 125 I assay appears to be superior to the 35 S assay in terms of sensitivity. Also, the production of 35 S-labeled 21-OH is expensive and time consuming, whereas 125 I-labeled 21-OH can be prepared easily, and handling and counting of this isotope are much more convenient than 35 S. Sera from 6 of 30 patients who were positive for ACA by S-labeled 21-OH. Sera were from 129 patients with autoimmune adrenal disease (see Table  1 ). Twenty-four sera negative in both assays plus 6 sera negative in the immunofluorescence but had no clinical signs of adrenal failure were negative for 21-OH Abs by 125 I assay. The reason for this discrepancy is not clear at present, but may be related to the specificity of the ACA immunofluorescence test. In the case of patients with overt adrenal failure (Addison's, APS type I and APS type II), all ACA positive sera in this group were also positive for 21-OH Abs by 125 I assay except 1. Furthermore, in this overt disease group, measurements with the 125 I assay seemed to be more sensitive, as 16 patient sera with lower levels (1-10 U/mL) of 21-OH Abs detectable by 125 I assay only showed positive for ACA by immunofluorescence in 8 cases (50%).
In our studies with the assay based on 125 I-labeled 21-OH, low levels of 21-OH Abs were detected in 6 of 243 (2.5%) healthy blood donors, 1 of 77 (1.3%) Graves' sera, 4 of 150 (2.7%) IDDM sera, and 1 of 67 (1.5%) sera from patients with Hashimoto's thyroiditis. 21-OH Abs were not detected in any of the myasthenia gravis, NIDDM, or POF sera studied. Unlabeled 21-OH (but not unlabeled GAD 65 or the yeast protein YP50) neutralized the 21-OH Abs in the healthy and control group sera, thus confirming the presence of specific 21-OH Abs. Furthermore, dilution studies and experiments with different concentrations of unlabeled 21-OH indicated that the 21-OH binding characteristics of the antibodies present in one of the healthy blood donor sera were similar to those of 21-OH Abs in Addison's sera.
To date, the prevalence of 21-OH Abs in healthy blood donors and in autoimmune control groups has not been studied extensively. 21-OH Abs were not detected in healthy blood donors sera or in autoimmune control sera in studies by Colls (6), Chen (4), and Uibo (26) . However, Falorni (25) found 21-OH Abs in 1 of 70 (1.4%) healthy blood donors using the 35 S assay. These results can be compared with the observation that low levels of GAD 65 Abs are also found in a small proportion of healthy blood donors or in patients with autoimmune diseases other than IDDM (9, 27, 28) .
Prevalences of ACA measured by immunofluorescence in large groups of sera from patients with autoimmune diseases (IDDM, autoimmune thyroid disease, myasthenia gravis, atrophic gastritis, and systemic lupus erythematosus) have been reported to range from below 1% to 5-8%, with the highest prevalence (from 2.5-20%) for patients with idiopathic hypoparathyroidism (29 -33) . ACA measured by immunofluorescence were not usually found in sera from healthy blood donors, except for 1 of 1127 sera in the study by Nerup (29) and 1 of 338 sera in the study by Betterle et al. (31) (32) (33) (34) (35) . The prevalence of 21-OH Abs measured by 125 I assay seems higher than that of ACA measured by immunofluorescence in the autoimmune control groups and healthy blood donors, and this probably reflects the greater sensitivity of the 125 I assay. Consequently, an assay is now available that will allow easy, reliable, routine assessment of adrenal autoimmunity. This type of assessment is particularly important in young patients who present with other autoimmune disorders, as the presence of adrenal Ab in this group of individuals indicates that adrenal insufficiency will develop soon (36) . Assessment of adrenal autoimmunity is also important in all patients who are suspected of having reduced adrenal reserve or adrenal failure (36 -41) . Further investigations with the new assay on the prevalence of 21-OH Abs in the general population and in different disease groups and on their pattern of inheritance should follow. In addition, studies of the effect of treatment or possible preventive measures on 21-OH Ab levels in individuals without overt adrenal failure may point to ways of delaying the onset of Addison's disease.
